14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
ATHE vs ECOR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over Alterity Therapeutics Limited (ATHE) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ATHE carries a Unified Composite Score of 39.2/100 (SELL) at $1.66 (N/M Forward P/E, -695.1% operating margin), whereas ECOR carries 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin).
Technical & Structure Timing Caution: ATHE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATHE vs ECOR. Trailing 12-month operating profitability (ATHE -695.1% vs ECOR -33.1%) and valuation multiples (ATHE N/M vs ECOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ATHE vs ECOR Key Questions & Quantitative Answers
As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over Alterity Therapeutics Limited (ATHE) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ATHE carries a Unified Composite Score of 39.2/100 (SELL) at $1.66 (N/M Forward P/E, -695.1% operating margin), whereas ECOR carries 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin). Technical & Structure Timing Caution: ATHE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ECOR leads the Growth & Scale pillar: ATHE posts -79.0% YoY revenue growth and +0.0% YoY earnings growth on $3.6M TTM revenue (92.7% gross margin, -695.1% operating margin), compared with ECOR at +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin). On trailing 12-month operating scale, ATHE generates $3.6M in USD-normalized revenue versus $38M for ECOR. In operating R&D and SG&A reinvestment, ATHE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ECOR.
ECOR screens cheaper on headline valuation multiples. ATHE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.0x EV/Revenue (unreported EBITDA margin), whereas ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATHE (-55.0% ROE) versus ECOR (-478.7% ROE) capital efficiency.
In options market volatility and institutional positioning, ATHE carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 102% Vol realized risk). By comparison, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.